The activity of the Jordanian company “HIKMA Pharmaceuticals” and its future program of development of its business in Tunisia were at the heart of a meeting that brought together Minister of Economy and Planning, Samir SAIED, with Ahmed. Al-Najjar, General Manager of HIKMA, who was accompanied by Mohamed SAMARA, Financial Director, and Moine ZAAFARANE, new project manager.
Ahmed Al-Najjar said that the company is at an advanced stage of preparation for the establishment of a new industrial unit in Sidi Thabet in the governorate of Ariana, with a total investment of about 30 million dinars.
The new plant will be equipped with the latest technology in line with international standards adopted in this field, stressed the general manager of HIKMA Pharmaceuticals, who added that this expansion is an affirmation of confidence in Tunisia as a privileged place for investment in its regional environment.
The CEO also said that the company plans to make Tunisia its strategic platform to move towards the African market.
HIKMA Pharmaceuticals has been operating in Tunisia for 30 years and has three industrial units that employ a total of about 250 people, two thirds of whom are higher education graduates. Its production of generic drugs is dedicated to supplying the local market and to exporting to many Arab and African countries.
HIKMA had entered into a non-binding clause in January 2021 with GSK, one of ADWYA’s licensors, with the aim of potentially acquiring its interests in certain entities that carry out pharmaceutical and consumer marketing and manufacturing activities on behalf of GSK in Egypt and Tunisia.
Two months later, HIKMA Pharmaceutical terminated discussions regarding the acquisition.
